ZA202101304B - Compounds for treating certain leukemias - Google Patents
Compounds for treating certain leukemiasInfo
- Publication number
- ZA202101304B ZA202101304B ZA2021/01304A ZA202101304A ZA202101304B ZA 202101304 B ZA202101304 B ZA 202101304B ZA 2021/01304 A ZA2021/01304 A ZA 2021/01304A ZA 202101304 A ZA202101304 A ZA 202101304A ZA 202101304 B ZA202101304 B ZA 202101304B
- Authority
- ZA
- South Africa
- Prior art keywords
- protein
- abl1
- abelson
- compounds
- bcr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862733029P | 2018-09-18 | 2018-09-18 | |
| US201962816637P | 2019-03-11 | 2019-03-11 | |
| US201962889929P | 2019-08-21 | 2019-08-21 | |
| PCT/US2019/051567 WO2020061086A2 (en) | 2018-09-18 | 2019-09-17 | Compounds for treating certain leukemias |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202101304B true ZA202101304B (en) | 2024-09-25 |
Family
ID=69774840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2021/01304A ZA202101304B (en) | 2018-09-18 | 2021-02-25 | Compounds for treating certain leukemias |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US10889571B2 (enExample) |
| EP (1) | EP3852745A4 (enExample) |
| JP (2) | JP7611832B2 (enExample) |
| KR (2) | KR20210061377A (enExample) |
| CN (3) | CN115448908B (enExample) |
| AU (2) | AU2019342102C1 (enExample) |
| BR (1) | BR112021004051A2 (enExample) |
| CA (1) | CA3110576A1 (enExample) |
| CL (1) | CL2021000637A1 (enExample) |
| CO (1) | CO2021004704A2 (enExample) |
| IL (2) | IL281427B2 (enExample) |
| MA (1) | MA53664A (enExample) |
| MX (2) | MX2021003093A (enExample) |
| NZ (1) | NZ773110A (enExample) |
| PE (2) | PE20211644A1 (enExample) |
| SG (1) | SG11202102367TA (enExample) |
| TW (1) | TWI826525B (enExample) |
| WO (1) | WO2020061086A2 (enExample) |
| ZA (1) | ZA202101304B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ773110A (en) | 2018-09-18 | 2024-11-29 | Terns Inc | Compounds for treating certain leukemias |
| LT3860998T (lt) | 2018-10-05 | 2024-06-25 | Annapurna Bio Inc. | Junginiai ir kompozicijos, skirti gydyti būkles, susijusias su apj receptoriaus aktyvumu |
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| BR112021017756A2 (pt) | 2019-03-11 | 2021-11-16 | Inflarx Gmbh | Piperidinila bicíclica fundida e compostos relacionados como moduladores do receptor c5a |
| EP3947369A4 (en) * | 2019-07-29 | 2022-10-05 | Ascentage Pharma (Suzhou) Co., Ltd. | HETEROCYCLIC COMPOUNDS AS BCR-ABL INHIBITORS |
| CA3154488A1 (en) | 2019-08-23 | 2021-03-04 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| CA3154391A1 (en) | 2019-09-12 | 2021-03-18 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| JP2024510935A (ja) * | 2021-03-03 | 2024-03-12 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | 甲状腺ホルモン受容体ベータアゴニスト化合物 |
| CN116375650B (zh) * | 2022-12-30 | 2025-08-05 | 浙江美诺华药物化学有限公司 | 一种替戈拉生中间体的制备方法 |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| TW202525293A (zh) | 2023-08-31 | 2025-07-01 | 美商拓臻製藥公司 | 用於治療癌症之組合 |
| WO2025226724A1 (en) | 2024-04-23 | 2025-10-30 | Terns Pharmaceuticals, Inc. | Bcr-abl1 inhibitors for use in treating cancer |
| CN120842151A (zh) * | 2024-04-26 | 2025-10-28 | 北京英飞智药科技有限公司 | 一种2-芳基苯并咪唑类化合物及其制备方法与应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA00011470A (es) | 1998-05-22 | 2002-10-17 | Avanir Pharmaceuticals | Analogos de bencimidazol como reguladores de la disminucion de ige. |
| SE0003476D0 (sv) | 2000-09-28 | 2000-09-28 | Astrazeneca Ab | Compounds |
| TW200304820A (en) * | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
| AR053364A1 (es) * | 2005-04-20 | 2007-05-02 | Smithkline Beecham | Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis |
| CN101553468A (zh) * | 2006-10-18 | 2009-10-07 | 诺瓦提斯公司 | 有机化合物 |
| PE20080888A1 (es) | 2006-10-18 | 2008-08-26 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1) |
| GB0800035D0 (en) | 2008-01-02 | 2008-02-13 | Glaxo Group Ltd | Compounds |
| WO2013033093A1 (en) | 2011-08-29 | 2013-03-07 | Biocryst Pharmaceuticals, Inc. | Heterocyclic compounds as janus kinase inhibitors |
| ES2670601T3 (es) | 2012-05-15 | 2018-05-31 | Novartis Ag | Derivados de benzamida para la inhibición de la actividad de ABL1, ABL2 y BCR-ABL1 |
| KR20150008406A (ko) | 2012-05-15 | 2015-01-22 | 노파르티스 아게 | Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체 |
| MX357305B (es) | 2012-05-15 | 2018-07-04 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de abl-1, abl-2, y bcr-abl1. |
| CA2874303C (en) | 2012-06-11 | 2020-10-13 | Ucb Biopharma Sprl | Tnf -alpha modulating benz imidazoles |
| CN103113355B (zh) | 2013-02-27 | 2014-08-13 | 无锡爱内特生物科技有限公司 | 一种Bcr/Abl酪氨酸激酶抑制剂及其制备方法和在治疗慢性粒细胞白血病中的应用 |
| GB201401086D0 (en) | 2014-01-23 | 2014-03-12 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| US9931342B2 (en) | 2016-02-02 | 2018-04-03 | Duke University | Compositions and methods for the treatment of cancer |
| CN109790144A (zh) | 2016-04-29 | 2019-05-21 | 爱仕达生物技术有限责任公司 | 新型杂环化合物作为酪氨酸激酶bcr-abl抑制剂 |
| JP6778833B2 (ja) | 2017-01-20 | 2020-11-04 | 深▲チェン▼市塔吉瑞生物医薬有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ， Ｉｎｃ． | キナーゼ活性を抑制するための（ヘテロ）アリールアミド類化合物 |
| CN108602800B (zh) | 2017-01-20 | 2019-08-27 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白激酶活性的(杂)芳基酰胺类化合物 |
| WO2018191146A1 (en) * | 2017-04-10 | 2018-10-18 | Navitor Pharmaceuticals, Inc. | Heteroaryl rheb inhibitors and uses thereof |
| US11649218B2 (en) | 2018-03-09 | 2023-05-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same |
| NZ773110A (en) | 2018-09-18 | 2024-11-29 | Terns Inc | Compounds for treating certain leukemias |
| US20240262842A1 (en) | 2021-04-27 | 2024-08-08 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras g12c mutant |
| KR20240089224A (ko) | 2021-09-30 | 2024-06-20 | 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 | 4-원 융합 고리형 화합물 및 이의 제조방법 및 용도 |
| TW202502333A (zh) | 2023-03-30 | 2025-01-16 | 大陸商江蘇豪森藥業集團有限公司 | 四元稠環類化合物鹽晶型及其製備方法和應用 |
| TW202525293A (zh) | 2023-08-31 | 2025-07-01 | 美商拓臻製藥公司 | 用於治療癌症之組合 |
-
2019
- 2019-09-17 NZ NZ773110A patent/NZ773110A/en unknown
- 2019-09-17 CN CN202210969394.6A patent/CN115448908B/zh active Active
- 2019-09-17 US US16/573,860 patent/US10889571B2/en active Active
- 2019-09-17 TW TW108133432A patent/TWI826525B/zh active
- 2019-09-17 MX MX2021003093A patent/MX2021003093A/es unknown
- 2019-09-17 CA CA3110576A patent/CA3110576A1/en active Pending
- 2019-09-17 PE PE2021000343A patent/PE20211644A1/es unknown
- 2019-09-17 KR KR1020217011001A patent/KR20210061377A/ko not_active Abandoned
- 2019-09-17 IL IL281427A patent/IL281427B2/en unknown
- 2019-09-17 MA MA053664A patent/MA53664A/fr unknown
- 2019-09-17 KR KR1020267002852A patent/KR20260019669A/ko active Pending
- 2019-09-17 JP JP2021539486A patent/JP7611832B2/ja active Active
- 2019-09-17 AU AU2019342102A patent/AU2019342102C1/en active Active
- 2019-09-17 EP EP19862388.6A patent/EP3852745A4/en active Pending
- 2019-09-17 CN CN202210968772.9A patent/CN115215838B/zh active Active
- 2019-09-17 PE PE2025001942A patent/PE20252740A1/es unknown
- 2019-09-17 IL IL322515A patent/IL322515A/en unknown
- 2019-09-17 SG SG11202102367TA patent/SG11202102367TA/en unknown
- 2019-09-17 BR BR112021004051-0A patent/BR112021004051A2/pt unknown
- 2019-09-17 WO PCT/US2019/051567 patent/WO2020061086A2/en not_active Ceased
- 2019-09-17 CN CN201980060896.3A patent/CN112770745B/zh active Active
-
2021
- 2021-02-25 ZA ZA2021/01304A patent/ZA202101304B/en unknown
- 2021-03-16 MX MX2023007714A patent/MX2023007714A/es unknown
- 2021-03-16 CL CL2021000637A patent/CL2021000637A1/es unknown
- 2021-04-15 CO CONC2021/0004704A patent/CO2021004704A2/es unknown
-
2023
- 2023-06-22 US US18/339,516 patent/US12240835B2/en active Active
-
2024
- 2024-12-20 AU AU2024287115A patent/AU2024287115A1/en active Pending
- 2024-12-24 JP JP2024227127A patent/JP2025066704A/ja active Pending
-
2025
- 2025-01-30 US US19/041,557 patent/US20250276961A1/en active Pending
- 2025-03-06 US US19/072,824 patent/US12454524B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023007714A (es) | Compuestos para tratar ciertas leucemias. | |
| PH12021551409A1 (en) | Kif18a inhibitors | |
| MX2021007104A (es) | Inhibidores de kif18a. | |
| MX2021013713A (es) | Celulas pluripotentes modificadas. | |
| WO2020132661A3 (en) | Inhibitors of fibroblast activation protein | |
| MXPA05010711A (es) | Compuestos y composiciones novedosos como inhibidores de proteina-quinasa. | |
| TR200201051T2 (tr) | Tirosin kinaz inhibitörleri. | |
| DE60028740D1 (de) | Phthalazinderivate zur behandlung von entzündlicher erkrankungen | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| MX2021006731A (es) | Inhibidores de proteínas quinasas activadas por mitógeno p38 en sitio no atp/catalítico. | |
| ATE478082T1 (de) | Phosphonate, monophosphonamidate, bisphosphonamidate zur behandlung von virenerkrankungen | |
| NO20054407L (no) | Cannabinoid reseptor ligander og deres anvendelser | |
| EA200200351A1 (ru) | Ингибиторы тирозинкиназы | |
| MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
| EP4631505A3 (en) | Crystalline forms and salt forms of a kinase inhibitor | |
| EP4048662A4 (en) | BICYCLO[1.1.1]PENTANE DOUBLE ZIP LEUCINE KINASE (DLK) INHIBITORS FOR DISEASE TREATMENT | |
| MY208067A (en) | Tubulysins and protein-tubulysin conjugates | |
| WO2018212361A8 (en) | Method of treating diseases associated with myd88 pathways using crispr-gndm system | |
| WO2020123330A3 (en) | Anti-alpha-synuclein antibodies and uses thereof | |
| MX2022005427A (es) | Composiciones biocidas y biopesticidas y metodos para controlar artropodos. | |
| MX2024007444A (es) | Inhibidores de cinasa met. | |
| WO2020046481A3 (en) | Methods for fructokinase mediation of alcohol craving and alcohol induced liver disease | |
| MX387025B (es) | Compuestos de anillo de siete miembros de pirimidina | |
| ZA202309651B (en) | Compositions and methods for treatment of ocular disease associated with angiogenesis | |
| EA200500934A1 (ru) | Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний |